Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its ...

Joseph Saseen, PharmD, discussed the importance of knowing lipoprotein a (Lp[a]) levels to enable clinicians to provide the best patient care and spread awareness to those who might be affected. Given ...

While low-density lipoprotein (LDL) particles are much more abundant than lipoprotein(a) [Lp(a)] particles and carry the greatest overall risk for coronary heart disease (CHD), on a per-particle basis ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Lipoprotein(a) levels, which are largely determined by genetics, appear to fluctuate over time, particularly in individuals with moderately elevated concentrations, a UK Biobank analysis shows. People ...

Baseline lipoprotein a, or Lp(a), levels are strongly associated with major adverse cardiovascular events (MACE) in high-risk patients with elevated triglyceride levels receiving statin therapy, a new ...

Please provide your email address to receive an email when new articles are posted on . About 20% of the global population and one in five U.S. adults have elevated levels of lipoprotein(a), a complex ...

Lipoprotein(a), the low-density lipoprotein (LDL)-like particle that is currently the focus of so much enthusiastic research, is significantly more atherogenic than LDL cholesterol, according to a ...